Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival – a Swedish Lymphoma Register Study
DOI:
https://doi.org/10.2340/1651-226X.2024.35238Keywords:
COVID-19, pandemic, lymphoma, incidence, mortalityAbstract
Background & purpose: The COVID-19 pandemic posed a large challenge for healthcare systems across the world. Comprehensive data on the impact of the COVID-19 pandemic on incidence and mortality in lymphoma are lacking.
Patients/methods: Using data from the Swedish lymphoma register, we compare incidence and 1-year survival of lymphoma patients in Sweden before (2017–2019) and during the pandemic (2020 and 2021).
Results: Fewer patients were diagnosed with lymphomas during March–June 2020, but the annual incidence rates for 2020 and 2021 were similar to those of 2017–2019. A larger proportion of patients presented with stage IV disease during 2021. There were no differences in other base-line characteristics nor application of active treatment in pre-pandemic and pandemic years. One-year overall survival was not inferior among lymphoma patients during the pandemic years compared to pre-pandemic years i.e., 2017–2019.
Interpretation: The COVID-19 pandemic had limited impact on the incidence and mortality of lymphoma in Sweden.
Downloads
References
Ludvigsson JF. The first eight months of Sweden’s COVID-19 strategy and the key actions and actors that were involved. Acta Paediatr. 2020;109(12):2459–71.
https://doi.org/10.1111/apa.15582 DOI: https://doi.org/10.1111/apa.15582
Ludvigsson JF. How Sweden approached the COVID-19 pandemic: summary and commentary on the National Commission Inquiry. Acta Paediatr. 2023;112(1):19–33.
https://doi.org/10.1111/apa.16535 DOI: https://doi.org/10.1111/apa.16535
Toscano O, Cosentino N, Campodonico J, et al. Acute myocardial infarction during the COVID-19 pandemic: an update on clinical characteristics and outcomes. Front Cardiovasc Med. 2021;8:648290.
https://doi.org/10.3389/fcvm.2021.648290 DOI: https://doi.org/10.3389/fcvm.2021.648290
Heer E, Ruan Y, Boyne DJ, et al. Impact of the COVID-19 pandemic on cancer diagnoses, stage and survival in Alberta. CMAJ. 2023;195(23):E804–12.
https://doi.org/10.1503/cmaj.221512 DOI: https://doi.org/10.1503/cmaj.221512
Morais S, Antunes L, Rodrigues J, et al. The impact of the coronavirus disease 2019 pandemic on the diagnosis and treatment of cancer in Northern Portugal. Eur J Cancer Prev. 2022;31(2):204–14.
https://doi.org/10.1097/CEJ.0000000000000686 DOI: https://doi.org/10.1097/CEJ.0000000000000686
Jacob L, Loosen SH, Kalder M, et al. Impact of the COVID-19 pandemic on cancer diagnoses in general and specialized practices in Germany. Cancers (Basel). 2021;13(3).
https://doi.org/10.3390/cancers13030408 DOI: https://doi.org/10.3390/cancers13030408
Eskander A, Li Q, Yu J, et al. Incident cancer detection during the COVID-19 pandemic. J Natl Compr Canc Netw. 2022;20(3):276–84.
https://doi.org/10.6004/jnccn.2021.7114 DOI: https://doi.org/10.6004/jnccn.2021.7114
Altmejd A, Östergren O, Björkegren E, et al. Inequality and COVID-19 in Sweden: relative risks of nine bad life events, by four social gradients, in pandemic vs. prepandemic years. Proc Natl Acad Sci. 2023;120(46):e2303640120.
https://doi.org/10.1073/pnas.2303640120 DOI: https://doi.org/10.1073/pnas.2303640120
Larfors G, Pahnke S, State M, et al. Covid-19 intensive care admissions and mortality among Swedish patients with cancer. Acta Oncol. 2021;60(1):32–4.
https://doi.org/10.1080/0284186X.2020.1854481 DOI: https://doi.org/10.1080/0284186X.2020.1854481
Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934–44.
https://doi.org/10.1002/ajh.26209 DOI: https://doi.org/10.1002/ajh.26209
Elliott EK, Hensen R, Haupt LM, et al. Global reported impacts of COVID-19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic. Eur J Haematol. 2023;110(5):457–69.
https://doi.org/10.1111/ejh.13926 DOI: https://doi.org/10.1111/ejh.13926
Jerkeman M. Swedish lymphoma registry 2000–2012. RCC Syd (Regional Cancer Center South). Lund; 2014.
Smedby KE. Validering av nationellt kvalitetsregister för lymfom 2022–2023. Unpublished data: Stockholm.
HMD. Human mortality database.
Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. 2022;6(1):327–38.
https://doi.org/10.1182/bloodadvances.2021005691 DOI: https://doi.org/10.1182/bloodadvances.2021005691
Additional Files
Published
How to Cite
License
Copyright (c) 2024 Sara Ekberg, Daniel Molin, Simon Pahnke, Fanny Bergström, Elsa Brånvall, Karin E. Smedby, Tove Wästerlid
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.